Drug Profile
Urabrelimab - Surface Oncology
Alternative Names: anti-CD-47 mAb-Surface Oncology; anti-CD-47 monoclonal antibody-Surface Oncology; CD47-mAb SRF-231; SRF-231Latest Information Update: 19 Sep 2023
Price :
$50
*
At a glance
- Originator Surface Oncology
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Haematological malignancies; Solid tumours
Most Recent Events
- 08 Sep 2023 Surface Oncology has been acquired by Coherus BioSciences
- 31 Dec 2022 Discontinued - Phase-I for Haematological malignancies (Late-stage disease, Monotherapy, Recurrent, Refractory metastatic disease, Second-line therapy or greater) in USA, Canada (Parenteral)
- 31 Dec 2022 Discontinued - Phase-I for Solid tumours (Late-stage disease, Monotherapy, Recurrent, Refractory metastatic disease, Second-line therapy or greater) in USA, Canada (Parenteral)